S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Buy THIS stock before Taiwan is attacked (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Buy THIS stock before Taiwan is attacked (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Buy THIS stock before Taiwan is attacked (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
66,000% upside on tiny biotech? (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
The single greatest medical breakthrough of all time? (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Buy THIS stock before Taiwan is attacked (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Will Plug Power’s Deal With Energy Vault Move The Needle? 

Inhibrx (INBX) Stock Forecast, Price & News

$23.39
-1.18 (-4.80%)
(As of 06/9/2023 ET)
Compare
Today's Range
$23.18
$24.75
50-Day Range
$16.96
$26.99
52-Week Range
$7.67
$34.72
Volume
290,806 shs
Average Volume
300,894 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00

Inhibrx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.9% Upside
$47.00 Price Target
Short Interest
Bearish
19.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
1.52mentions of Inhibrx in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.06) to ($3.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

218th out of 988 stocks

Biological Products, Except Diagnostic Industry

28th out of 158 stocks


INBX stock logo

About Inhibrx (NASDAQ:INBX) Stock

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

INBX Stock News Headlines

Inhibrx (NASDAQ:INBX) Shares Down 5.5%
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Inhibrx (NASDAQ:INBX) Shares Gap Down to $25.15
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Inhibrx (NASDAQ:INBX) Trading 7.2% Higher
Inhibrx: Undercovered Company With Good Potential
Inhibrx (NASDAQ:INBX) Trading Down 7.4%
See More Headlines

INBX Price History

INBX Company Calendar

Last Earnings
11/09/2021
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+100.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-145,230,000.00
Net Margins
-12,725.62%
Pretax Margin
-12,725.39%

Debt

Sales & Book Value

Annual Sales
$2.19 million
Book Value
$1.33 per share

Miscellaneous

Free Float
33,933,000
Market Cap
$1.02 billion
Optionable
Not Optionable
Beta
2.85

Key Executives

  • Mr. Mark Paul LappeMr. Mark Paul Lappe (Age 56)
    Founder, Chairman, Pres & CEO
    Comp: $1.02M
  • Dr. Brendan P. Eckelman Ph.D. (Age 44)
    Founder & Chief Scientific Officer
    Comp: $704k
  • Ms. Kelly Devine Deck B.S. (Age 42)
    CPA, M.S., Exec. VP & CFO
    Comp: $531.17k
  • Mr. Quinn L. Deveraux
    Founder
  • Dr. Ashraf Amanullah (Age 55)
    Exec. VP & Chief Technical Operations Officer
  • Ms. Leah Pollema J.D.
    VP, Corp. Sec. & Gen. Counsel
  • Dr. Charbel Helaihel Pharm.D.
    VP of Marketing & Commercial Planning
  • Mr. Jeffrey J. JensenMr. Jeffrey J. Jensen
    Exec. VP & Chief Clinical Operations Officer
  • Mr. David Matly M.B.A.
    Exec. VP & Chief Commercial Officer
  • Dr. Carlos Bais Ph.D.
    Exec. VP of Translational Sciences













INBX Stock - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INBX shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price forecast for 2023?

4 analysts have issued 12 month target prices for Inhibrx's stock. Their INBX share price forecasts range from $35.00 to $60.00. On average, they expect the company's share price to reach $47.00 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2023?

Inhibrx's stock was trading at $24.64 at the start of the year. Since then, INBX shares have decreased by 5.1% and is now trading at $23.39.
View the best growth stocks for 2023 here
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) issued its earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.53 million for the quarter, compared to analysts' expectations of $1 million. Inhibrx had a negative trailing twelve-month return on equity of 1,961.44% and a negative net margin of 12,725.62%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is Inhibrx's stock symbol?

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.29%), BlackRock Inc. (5.35%), State Street Corp (4.76%), FMR LLC (3.69%), ArrowMark Colorado Holdings LLC (2.16%) and Geode Capital Management LLC (1.40%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibrx's stock price today?

One share of INBX stock can currently be purchased for approximately $23.39.

How much money does Inhibrx make?

Inhibrx (NASDAQ:INBX) has a market capitalization of $1.02 billion and generates $2.19 million in revenue each year. The company earns $-145,230,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis.

How many employees does Inhibrx have?

The company employs 132 workers across the globe.

How can I contact Inhibrx?

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.

This page (NASDAQ:INBX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -